Trials / Completed
CompletedNCT03503292
Pharmacogenomics and Post-Operative Nausea and Vomiting
Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Granisetron | Rapid metabolizer will receive 1mg IV Granisetron |
| DRUG | Ondansetron | Poor or normal metabolizers will receive 4mg Ondansetron IV |
Timeline
- Start date
- 2018-05-02
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
- First posted
- 2018-04-19
- Last updated
- 2020-10-28
- Results posted
- 2020-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03503292. Inclusion in this directory is not an endorsement.